PROCEPT BioRobotics (PRCT)
(Delayed Data from NSDQ)
$61.74 USD
+1.13 (1.86%)
Updated May 2, 2024 04:00 PM ET
After-Market: $61.78 +0.04 (0.06%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
PROCEPT BioRobotics Corporation (PRCT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$55.83 | $63.00 | $47.00 | -7.89% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for PROCEPT BioRobotics Corporation comes to $55.83. The forecasts range from a low of $47.00 to a high of $63.00. The average price target represents a decline of 7.89% from the last closing price of $60.61.
Analyst Price Targets (6 )
Broker Rating
PROCEPT BioRobotics Corporation currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.25 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, seven are Strong Buy, representing 87.5% of all recommendations. A month ago, Strong Buy represented 87.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/1/2024 | William Blair | Brandon Vazquez | Strong Buy | Strong Buy |
4/26/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
2/28/2024 | BTIG | Ryan Zimmerman | Hold | Hold |
12/22/2023 | Truist Securities | Richard Newitter | Strong Buy | Strong Buy |
10/16/2023 | SVB Securities | Michael Kratky | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.25 |
ABR (Last week) | 1.25 |
# of Recs in ABR | 8 |
Average Target Price | $55.83 |
LT Growth Rate | 17.90% |
Industry | Medical - Instruments |
Industry Rank by ABR | 145 of 252 |
Current Quarter EPS Est: | -0.54 |